Brian Smith, MD
Family Medicine · Versailles, KYNPI 1992749873
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Johnson & Johnson at 58.8% of the total. Reporting peaked in 2019 at $13,410 and has fallen 94.9% since, to $688 in 2025. Among family medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 471 payments — averaging $48.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$13K
- Alnylam Pharmaceuticals Inc.$1K
- Bayer$1K
- Modernatx, Inc.$1K
- AbbVie$875
- Pfizer$365
- plus $4K from 54 others
Across 569 payments — averaging $13,454 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$6.6M
- Merck$397K
- Bavarian Nordic A/s$276K
- Pfizer$161K
- Genentech, Inc.$109K
- AstraZeneca$59K
- plus $104K from 4 others
What the payments were for
- Speaking & faculty fees$12,23454%
- Travel & lodging$2,93113%
- Food & beverage$7,25232%
- Education$2221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,638 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 37 | $561,556 |
| JardianceEmpagliflozin | 149 | $159,352 |
| EliquisApixaban | 225 | $147,886 |
| IngrezzaValbenazine Tosylate | 16 | $138,653 |
| TrulicityDulaglutide | 132 | $128,613 |
| OzempicSemaglutide | 90 | $107,961 |
| MounjaroTirzepatide | 71 | $78,136 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $76,794 |
| XareltoRivaroxaban | 91 | $70,730 |
| SpravatoEsketamine Hcl | 38 | $69,310 |
| XifaxanRifaximin | 13 | $46,636 |
| EntrestoSacubitril/Valsartan | 41 | $39,982 |
| LinzessLinaclotide | 57 | $39,144 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 176 | $38,629 |
| FarxigaDapagliflozin Propanediol | 34 | $36,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $188 | $561,55637 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $269 | $206,748203 claims |
| PfizerEliquis, Abrysvo | $365 | $176,409315 claims |
| Johnson & JohnsonXarelto, Spravato, Risperdal Consta | $13,309 | $173,937141 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $355 | $172,408167 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $22 | $138,65316 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $312 | $129,001299 claims |
| Novo NordiskOzempic | $193 | $107,96190 claims |
| AbbVieLinzess, Vraylar, Viberzi | $875 | $83,13285 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $98 | $46,63613 claims |
| NovartisEntresto | $172 | $39,98241 claims |
| AstraZenecaFarxiga | $28 | $36,50734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Versailles
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
- Derek JonesAshland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.